Drug Price Trends for PERINDOPRIL ERBUMINE

Average Pharmacy Cost for PERINDOPRIL ERBUMINE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
PERINDOPRIL ERBUMINE 4 MG TAB	65862-0287-01	0.49843	EACH	2025-03-19
PERINDOPRIL ERBUMINE 8 MG TAB	65862-0288-01	0.56920	EACH	2025-03-19
PERINDOPRIL ERBUMINE 4 MG TAB	65862-0287-01	0.49910	EACH	2025-02-19
PERINDOPRIL ERBUMINE 8 MG TAB	65862-0288-01	0.55277	EACH	2025-02-19
PERINDOPRIL ERBUMINE 8 MG TAB	65862-0288-01	0.54964	EACH	2025-01-22
PERINDOPRIL ERBUMINE 4 MG TAB	65862-0287-01	0.49991	EACH	2025-01-22

Market Analysis and Price Projections for Perindopril Erbumine

Introduction to Perindopril Erbumine

Perindopril erbumine is an angiotensin-converting enzyme (ACE) inhibitor used primarily in the treatment of hypertension, congestive heart failure, and to reduce cardiovascular risk in patients with hypertension or post-myocardial infarction and stable coronary disease[4].

Market Size and Growth

The global market for perindopril erbumine API has witnessed significant growth in recent years. As of 2023, the market value was substantial, and it is anticipated to continue growing until 2031. The market is expected to expand from its current value to reach a projected value of several billion USD by the end of the forecast period[2].

Market Segmentation

The perindopril erbumine API market is segmented based on several key factors:

Type

• The market is categorized into purity levels, primarily >99% and <99%. The higher purity segment is often preferred due to its consistency and reliability in pharmaceutical applications[2].

Application

• The primary application is in the production of perindopril erbumine tablets. Other applications may include research and development, and various pharmaceutical formulations[2].

Geographical Regions

• The market is analyzed across North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. Each region has its own market dynamics, driven by local healthcare policies, economic conditions, and patient demographics[2].

Market Dynamics

Drivers

• The increasing prevalence of hypertension and cardiovascular diseases globally is a significant driver for the perindopril erbumine API market. Growing awareness about the importance of early treatment and prevention of these conditions also contributes to market growth[2].

Restraints

• High production costs and stringent regulatory requirements can act as restraints. Additionally, the availability of generic alternatives and combination therapies can impact the market for perindopril erbumine[3].

Opportunities

• Emerging markets in Asia-Pacific and Latin America offer significant opportunities due to their large patient populations and growing healthcare expenditure. Innovations in drug delivery systems and combination therapies also present potential growth avenues[2].

Challenges

• The market faces challenges such as patent expirations, which can lead to increased competition from generic drugs. Moreover, the cost-effectiveness of combination therapies over monotherapies can impact the demand for perindopril erbumine[3].

Price Projections

Cost Analysis

• Perindopril erbumine is generally more expensive than some other antihypertensive drugs, especially when compared to monotherapies or fixed-dose combinations with diuretics. For instance, the annual cost of perindopril erbumine can range from $238 to $413 per patient, which is higher than some other ACE inhibitors or calcium channel blockers (CCBs) used as monotherapy[3].

Pricing Trends

• The price of perindopril erbumine tablets can vary based on the region and the specific formulation. For example, in New Zealand, the price of Coversyl (a brand of perindopril erbumine) changed in 2022, with the 2mg and 4mg tablets priced at $1.58 and $2.95 per 30 tablets, respectively. An 8mg tablet was also introduced, subject to regulatory approval[5].

Regulatory Environment

• Regulatory approvals play a crucial role in the market dynamics of perindopril erbumine. For instance, Health Canada approved APO-Perindopril Arginine (a different salt form of perindopril) based on comparative bioavailability studies with Coversyl (perindopril erbumine). This approval highlights the importance of bioequivalence studies in ensuring the safety and efficacy of generic or alternative formulations[4].

Key Players and Competition

• The market for perindopril erbumine is competitive, with several key players involved in its production and distribution. Companies like Servier Canada Inc. and Apotex Inc. are prominent in this market. The competition is further intensified by the presence of generic alternatives and combination therapies[4][5].

Consumer Behavior and Economic Impact

• Consumer behavior is influenced by factors such as the availability of generic options, the cost of treatment, and the efficacy of the drug. The economic impact of perindopril erbumine on healthcare budgets is significant, especially considering its use in long-term treatment plans for chronic conditions like hypertension[3].

Future Outlook

• The future outlook for the perindopril erbumine API market is positive, driven by the increasing demand for effective antihypertensive treatments. Innovations in drug formulations and the expansion into emerging markets are expected to contribute to sustained growth.

"The market is poised for noteworthy and impactful development," indicating a strong growth trajectory from 2023 to 2031[2].

Key Takeaways

• Market Growth: The perindopril erbumine API market is expected to grow significantly until 2031.
• Segmentation: The market is segmented by type, application, and geographical regions.
• Drivers and Restraints: Increasing prevalence of hypertension and regulatory challenges are key drivers and restraints.
• Price Projections: Prices vary by region and formulation, with a general trend of being more expensive than some other antihypertensive drugs.
• Regulatory Environment: Bioequivalence studies are crucial for regulatory approvals.
• Competition: The market is competitive with several key players and generic alternatives.

FAQs

1. What is the primary use of perindopril erbumine?

   • Perindopril erbumine is primarily used in the treatment of hypertension, congestive heart failure, and to reduce cardiovascular risk in patients with hypertension or post-myocardial infarction and stable coronary disease[4].

2. How is the perindopril erbumine API market segmented?

   • The market is segmented based on type (purity levels), application (primarily perindopril erbumine tablets), and geographical regions[2].

3. What are the key drivers for the perindopril erbumine API market?

   • The increasing prevalence of hypertension and cardiovascular diseases, along with growing awareness about early treatment, are significant drivers[2].

4. How does the cost of perindopril erbumine compare to other antihypertensive drugs?

   • Perindopril erbumine is generally more expensive than some other antihypertensive drugs, especially when compared to monotherapies or fixed-dose combinations with diuretics[3].

5. What is the regulatory environment like for perindopril erbumine?

   • Regulatory approvals are based on comparative bioavailability studies, ensuring the safety and efficacy of the drug. Health Canada and other regulatory bodies play a crucial role in this process[4].

Sources

1. Global Perindopril Erbumine API Market Research Report 2024 - Market Research Reports[1].
2. Perindopril Erbumine API Market Size, Scope And Forecast Report - Market Research Intellect[2].
3. CDR Pharmacoeconomic Review Report for Viacoram - Canadian Agency for Drugs and Technologies in Health[3].
4. Regulatory Decision Summary for APO-Perindopril Arginine - Health Canada[4].
5. Decision for the supply of perindopril tablets - Pharmac New Zealand[5].